The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab Drives Regulatory T Cell Expansion by Binding to Membrane TNF

Adalimumab Drives Regulatory T Cell Expansion by Binding to Membrane TNF

June 9, 2016 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The anti-tumor necrosis factor (TNF) antibody adalimumab drives regulatory T cell (Treg) expansion in rheumatoid arthritis (RA) by binding to membrane TNF, researchers from the UK report.

You Might Also Like
  • TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis
  • Protein Phosphatase 2A and Regulatory T Cell Function Researched
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review

“These results show that adalimumab enhances the anti-inflammatory actions of TNF to increase regulatory T cell activity,” Dr. Michael R. Ehrenstein from University College London, tells Reuters Health by email. “The data also supports the notion that membrane TNF stimulates the actions of regulatory T cells.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Ehrenstein and Dr. Dao Xuan Nguyen showed previously that adalimumab, but not etanercept (a soluble TNF receptor), increased Treg cell numbers in patients with RA and that these Treg cells could suppress the highly inflammatory cytokine interleukin-17 (IL-17).

It was unclear, however, why etanercept, which was equally effective for treating RA, lacked Treg cell modulatory properties, so they undertook further studies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After showing once again that adalimumab increased functionally suppressive Treg cells in rheumatoid arthritis patients, they demonstrated that adalimumab bound to membrane TNF expressed by rheumatoid arthritis monocytes and promoted binding between monocyte membrane TNF and TNF receptor II (TNF-RII) expressed by Treg cells.

This interaction triggered expansion of the Treg cell subset, according to the June 6 online report in the Journal of Experimental Medicine.

Adalimumab enhanced IL-2 production and increased STAT5 phosphorylation, which were required for adalimumab-driven Treg cell expansion.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

These effects were not reproduced by exposure to etanercept.

“It would have been predicted that adalimumab inhibited the binding of its target,” Dr. Ehrenstein says. “In this way adalimumab blocks the inflammatory actions of soluble TNF but enhances the anti-inflammatory effects of membrane TNF at least with respect to the latter’s interaction with TNF receptor II expressed on regulatory T cells.”

“Also of relevance, adalimumab appeared to achieve this effect only in a narrow concentration range, which coincided with serum concentrations in patients responding to adalimumab,” he explains.

“Therefore, anti-TNF antibodies appear to be the first example of a therapeutic cytokine inhibitor that simultaneously boosts the pro-resolution forces driven by that pathway whilst still blocking the harmful actions of TNF, thereby highlighting a novel therapeutic paradigm,” Dr. Ehrenstein says. “This could have implications for other therapeutic antibodies used for a wide variety of indications.”

“Greater understanding of biologic therapies and their mechanisms of action could lead to the development of novel therapeutic approaches as well as defining biomarkers of disease response,” Dr. Ehrenstein says. “If regulatory T cells could be harnessed in such a way that disease does not return when therapy is stopped, this could lead to long-term disease remission.”

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, Anti-TNF, etanercept, regulatory T cells, Rheumatoid Arthritis (RA), T cell

You Might Also Like:
  • TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis
  • Protein Phosphatase 2A and Regulatory T Cell Function Researched
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • Adalimumab & Infliximab Remain in Newborns after Delivery

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.